Raymond James Maintains Outperform Rating for PTC Therapeutics: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Raymond James has maintained its Outperform rating for PTC Therapeutics (NASDAQ:PTCT) but lowered its price target from $58.00 to $55.00. PTC Therapeutics' shares are currently trading down 2.83% at $39.18 per share. A move to the new target price would represent a 40.38% increase from the current share price.
August 04, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Raymond James has maintained its Outperform rating for PTC Therapeutics but lowered its price target. This could potentially lead to a short-term decrease in the stock price.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The decision by Raymond James to maintain its Outperform rating indicates a positive outlook for PTC Therapeutics. However, the lowering of the price target could lead to a short-term decrease in the stock price as it may be interpreted as a less optimistic view on the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100